SCHEMBL6297541

SCHEMBL6297541

NC(=O)[C@]1(CO)O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.58
▸ WDR77 Q9BQA1 1/20 0.58
▸ AHCY P23526 5/20 0.57
▸ ADORA2A P29274 3/20 0.57
▸ ADORA2B P29275 3/20 0.57
▸ HSP90B1 P14625 2/20 0.57
▸ ADORA3 P0DMS8 6/20 0.56
▸ ADORA1 P30542 2/20 0.56
▸ DPP4 P27487 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ SLC28A1 O00337 1/20 0.56
▸ MAP3K7 O43318 1/20 0.56
▸ SLC28A2 O43868 1/20 0.56
▸ GAPDH P04406 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ STAT6 P42226 1/20 0.56
▸ PI4KA P42356 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ PI4K2B Q8TCG2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11518921 1.00 PRMT5 (0.58) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL9024927 0.91 PRMT5 (0.58) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL9024944 0.91 PRMT5 (0.58) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL561654 0.82 PRMT5 (0.64) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL561516 0.82 PRMT5 (0.64) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL561515 0.82 PRMT5 (0.64) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL6426564 0.81 PRMT5 (0.65) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL14946260 0.81 PRMT5 (0.65) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL14853754 0.81 PRMT5 (0.65) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL2318607 0.81 PRMT5 (0.65) PRMT5WDR77AHCYADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903079-B2 Nucleoside compounds and compositions thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2005-06-07 — — US disclosed
US-20030149050-A1 Inhibitors of inflammation and reperfusion injury and methods of use thereof INOTEK CORP. 2003-08-07 — — US disclosed
US-6534651-B2 Substituted isoindolinone derivatives INOTEK PHARMACEUTICALS CORP. 2003-03-18 — — US disclosed
US-20020095044-A1 Inhibitors of inflammation and reperfusion injury and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION 2002-07-18 — — US disclosed
WO-2001077075-A2 INHIBITORS OF INFLAMMATION AND REPERFUSION INJURY INOTEK CORPORATION (US) 2001-10-18 — — WO disclosed
US-4167565-A Adenosine-5'-carboxamides and method of use ABBOTT LABORATORIES (US) 1979-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020095044-A1 Inhibitors of inflammation and reperfusion injury and methods of use thereof IL1B, PTGS1, MMP8 PRMT5 1966/4885WDR77 3732/4885AHCY 2416/4885
US-20030149050-A1 Inhibitors of inflammation and reperfusion injury and methods of use thereof IL1B, PTGS1, MMP8 PRMT5 1966/4885WDR77 3732/4885AHCY 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback